Gabriel Sauvage

Gabriel Sauvage

Auto-generated profile, based on publicly available information

Gabriel Sauvage

Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
RZReza Zonozi
Reza Zonozi
LWLucy C. Walters
Lucy C. Walters
ASAaron Shulkin
Aaron Shulkin
VNVivek Naranbhai
Vivek Naranbhai
PNPravarut Nithagon
Pravarut Nithagon
GGGaurav D. Gaiha
Gaurav D. Gaiha
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe disease and mortality from coronavirus disease 2019 (COVID-19), but the immune responses and clinical outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have yet to be fully defined. Here, we evaluate the cellular immune responses after both SARS-CoV-2 infection and vaccination in patients receiving the anti-CD20 therapy rituximab (RTX) and those with low B cell counts due to common variable immune deficiency (CVID) disease. Assessment of effector and memory CD4 + and CD8 + T cell responses to SARS-CoV-2 revealed elevated reactivity and proliferative capacity after both infection and vaccination in B cell–deficient individuals, particularly within the CD8 + T cell compartment, in comparison with healthy controls. Evaluation of clinical outcomes demonstrates that vaccination of RTX-treated individuals was associated with about 4.8-fold reduced odds of moderate or severe COVID-19 in the absence of vaccine-induced antibodies. Analysis of T cell differentiation demonstrates that RTX administration increases the relative frequency of naïve CD8 + T cells, potentially by depletion of CD8 + CD20 dim T cells, which are primarily of an effector memory or terminal effector memory (TEMRA) phenotype. However, this also leads to a reduction in preexisting antiviral T cell immunity. Collectively, these data indicate that individuals with B cell deficiencies have enhanced T cell immunity after both SARS-CoV-2 infection and vaccination that potentially accounts for reduced hospitalization and severe disease from subsequent SARS-CoV-2 infection.

11 December 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
RZReza Zonozi
Reza Zonozi
FCFrank B Cortazar
Frank B Cortazar
AJAnushya Jeyabalan
Anushya Jeyabalan
GSGabriel Sauvage
Gabriel Sauvage
PNPravarut Nithagon
Pravarut Nithagon
JNJohn L Niles
John L Niles
Objective To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. Methods We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level. Evaluations were conducted every 3 months. The primary endpoint was clinical relapse, defined as a modified BVAS/WG >0 by 36 months. Secondary endpoints included serious adverse events (SAEs) and rituximab exposure. Results 115 patients were enrolled. Median follow-up time was 4.1 years (IQR 2.5–5.0). By Kaplan-Meier analysis, 4.1% (95% CI 1.0 to 15.6) of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA arm, at 3 years after study entry (log-rank p=0.045). Total SAEs, including infectious SAEs, and deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049). In the B cell arm, patients received a mean of 3.6 (SD 2.4) infusions (3.6 g) per person over the median study follow-up time of 4.1 years, compared with 0.5 (SD 1.4) infusions (0.5 g) per patient in the ANCA arm (p<0.001). Conclusions Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy. Trial registration number NCT02749292.

29 July 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
HSHarish Seethapathy
Harish Seethapathy
AJAyman Al Jurdi
Ayman Al Jurdi
OEOrhan Efe
Orhan Efe
AJAnushya Jeyabalan
Anushya Jeyabalan
GSGabriel Sauvage
Gabriel Sauvage
JNJohn L. Niles
John L. Niles
An abstract is unavailable. This article is available as a PDF only.